ReviewRevista de neurologia2024

[New therapeutic era for migraine attacks with recently approved monoclonal antibodies, ditans and gepants].

A Mínguez-Olaondo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.